Excedrin (migraine Relief) is a drug owned by Haleon Us Holdings Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 14, 2017. Details of Excedrin (migraine Relief)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5972916 | Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine |
Jul, 2017
(7 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Excedrin (migraine Relief) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Excedrin (migraine Relief)'s family patents as well as insights into ongoing legal events on those patents.
Excedrin (migraine Relief)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Excedrin (migraine Relief)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 14, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Excedrin (migraine Relief) Generic API suppliers:
Acetaminophen; Aspirin; Caffeine is the generic name for the brand Excedrin (migraine Relief). 3 different companies have already filed for the generic of Excedrin (migraine Relief), with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Excedrin (migraine Relief)'s generic
How can I launch a generic of Excedrin (migraine Relief) before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Excedrin (migraine Relief)'s patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Excedrin (migraine Relief)'s sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Excedrin (migraine Relief) -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 250 mg/ 250 mg/ 65 mg |
About Excedrin (migraine Relief)
Excedrin (Migraine Relief) is a drug owned by Haleon Us Holdings Llc. It is used for relieving migraine pain and associated symptoms like photophobia, phonophobia, nausea, and functional disability. Excedrin (Migraine Relief) uses Acetaminophen; Aspirin; Caffeine as an active ingredient. Excedrin (Migraine Relief) was launched by Haleon Us Holdings in 1998.
Approval Date:
Excedrin (migraine Relief) was approved by FDA for market use on 14 January, 1998.
Active Ingredient:
Excedrin (migraine Relief) uses Acetaminophen; Aspirin; Caffeine as the active ingredient. Check out other Drugs and Companies using Acetaminophen; Aspirin; Caffeine ingredient
Treatment:
Excedrin (migraine Relief) is used for relieving migraine pain and associated symptoms like photophobia, phonophobia, nausea, and functional disability.
Dosage:
Excedrin (migraine Relief) is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 250MG;250MG;65MG | TABLET | Over the counter | ORAL |